AstraZeneca Receives FDA Approval for Breast Cancer Treatment
13 January 2018 - 4:01AM
Dow Jones News
By Adam Clark
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food &
Drug Administration agency has approved its Lynparza drug for
treatment of patients with metastatic breast cancer.
The biopharmaceutical company said Lynparza reduced the risk of
disease progression or death by 42% compared with standard
chemotherapy in clinical trials. The authorization is the third
indication approved for Lynparza in the U.S., where it is already
used to treat ovarian cancer.
AstraZeneca said that as part of its oncology collaboration with
Merck & Co. Inc. (MRK) it will receive $70 million in
externalization revenue following the new approval. The agreement
sees AstraZeneca potentially eligible for over $6 billion in
externalization revenue in the form of sales and approval-related
payments, said the company.
AstraZeneca shares at 1619 GMT were up 13 pence, or 0.3%, at
5,145 pence.
Write to Adam Clark at adam.clark@dowjones.com
(END) Dow Jones Newswires
January 12, 2018 11:46 ET (16:46 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024